Literature DB >> 23296949

Regaining tolerance to a self-antigen by the modified vaccination technique.

Arpad Zsigmond Barabas1, Chad Douglas Cole, Rene Lafreniere, Donald Mackay Weir.   

Abstract

Autoimmune diseases are initiated and maintained by complex immunopathological processes in environmental and genetic factor predisposed patients. In certain autoimmune diseases, the etiologies and pathogenesis of the conditions are quite well understood; yet in others, controversy surrounds as to why and how auto-injurious processes start. Clinical and laboratory examinations reasonably well define the state of progression/remission of an autoimmune disease and allow treatment according to observed findings. However, none of the presently employed treatment options are specific. In fact, they are all nonspecific in their actions and have undesirable side effects. Over the years, experiments carried out in animals have shed light on the complex immunopathological processes which contribute to disease development and progression. At least one experimental autoimmune kidney disease-which we shall describe-helps to understand how pathogenic autoimmune responses can be terminated specifically, without side effects. Since the new vaccination method-that we call modified vaccination technique-was successfully implemented in an experimental autoimmune disease model called slowly progressive Heymann nephritis for the termination of pathogenic immune responses by a target antigen-specific treatment modality, we shall highlight its use in providing insight to physicians and autoimmunologists for its future implementation in human autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23296949     DOI: 10.1007/s12016-012-8350-y

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  79 in total

1.  Experimental glomerulonephritis.

Authors:  D J Salant; A V Cybulsky
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

2.  Formation of immune deposits and disease.

Authors:  G Andres; J R Brentjens; P R Caldwell; G Camussi; S Matsuo
Journal:  Lab Invest       Date:  1986-11       Impact factor: 5.662

3.  Auto-immune nephritis in rats.

Authors:  A Z Barabas; R Lannigan
Journal:  J Pathol       Date:  1969-03       Impact factor: 7.996

4.  Glomerular antigens in Heymann's nephritis: reactivity of eluted and circulating antibody.

Authors:  T J Neale; C B Wilson
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

Review 5.  The role of autoimmunologists in investigating and treating autoimmune disorders.

Authors:  Arpad Zsigmond Barabas; Chad Douglas Cole; Richard Milton Graeff; Rene Lafreniere; Donald Mackay Weir
Journal:  Autoimmun Rev       Date:  2010-09-29       Impact factor: 9.754

6.  Do selected drugs increase the risk of lupus? A matched case-control study.

Authors:  W Marieke Schoonen; Sara L Thomas; Emily C Somers; Liam Smeeth; Joseph Kim; Stephen Evans; Andrew J Hall
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

Review 7.  Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)

Authors:  D Kerjaschki; T J Neale
Journal:  J Am Soc Nephrol       Date:  1996-12       Impact factor: 10.121

Review 8.  B cell targeted therapy in autoimmunity.

Authors:  Miri Blank; Yehuda Shoenfeld
Journal:  J Autoimmun       Date:  2007-03-27       Impact factor: 7.094

9.  Effect of reimmunization with Fx1A late in the course of Heymann nephritis.

Authors:  B Noble; J B Van Liew; J R Brentjens; G A Andres
Journal:  Lab Invest       Date:  1982-11       Impact factor: 5.662

10.  Autologous immune complex nephritis induced with renal tubular antigen. I. Identification and isolation of the pathogenetic antigen.

Authors:  T S Edgington; R J Glassock; F J Dixon
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Antibody-initiated beneficial and harmful immune responses.

Authors:  Arpad Zsigmond Barabas; Chad Douglas Cole; Rene Lafreniere
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

2.  Tolerance, loss of tolerance and regaining tolerance to self by immune-mediated events.

Authors:  Arpad Zsigmond Barabas; Chad Douglas Cole; Richard Milton Graeff; Rene Lafreniere; Donald Mackay Weir
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.